
Quarterly report 2025-Q3
added 10-23-2025
West Pharmaceutical Services Financial Statements 2011-2025 | WST
Annual Financial Statements West Pharmaceutical Services
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
15.4 B | 26.2 B | 22.8 B | 28.8 B | 20.7 B | 11.7 B | 7.83 B | 7.45 B | 6.12 B | 4.12 B | 3.5 B | 3.35 B | 2.02 B | 1.36 B |
Shares |
73 M | 74.3 M | 74.4 M | 74.4 M | 73.9 M | 74 M | 73.9 M | 73.9 M | 73.3 M | 72 M | 70.9 M | 69.6 M | 68 M | 67.4 M |
Historical Prices |
211 | 352 | 307 | 387 | 280 | 150 | 104 | 85.8 | 80.6 | 60.2 | 52.7 | 43.5 | 28.5 | 19.3 |
Net Income |
493 M | 593 M | 586 M | 662 M | 346 M | 242 M | 207 M | 151 M | 144 M | 95.6 M | 127 M | 112 M | 80.7 M | 75.5 M |
Revenue |
2.89 B | 2.95 B | 2.89 B | 2.83 B | 2.15 B | 1.84 B | 1.72 B | 1.6 B | 1.51 B | 1.4 B | 1.42 B | 1.37 B | 1.27 B | 1.19 B |
Cost of Revenue |
1.89 B | 1.82 B | 1.75 B | 1.66 B | 1.38 B | 1.23 B | 1.17 B | 1.09 B | 1.01 B | 944 M | 974 M | 934 M | 879 M | 853 M |
Gross Profit |
998 M | 1.13 B | 1.14 B | 1.18 B | 768 M | 606 M | 545 M | 513 M | 501 M | 456 M | 448 M | 435 M | 388 M | 339 M |
Operating Income |
570 M | 676 M | 734 M | 752 M | 407 M | 297 M | 240 M | 226 M | 195 M | 129 M | 182 M | 162 M | 135 M | 110 M |
Interest Expense |
-1 M | 3 M | -51.3 M | 8.2 M | 8.2 M | 8.5 M | 8.4 M | 7.8 M | 8.1 M | 14.1 M | 16.5 M | 17 M | 16.7 M | 18.2 M |
EBITDA |
725 M | 813 M | 855 M | 875 M | 516 M | 408 M | 352 M | 334 M | 319 M | 269 M | 272 M | 247 M | 213 M | 195 M |
Operating Expenses |
- | - | - | - | - | 301 M | 298 M | 275 M | 273 M | 276 M | 266 M | 273 M | 251 M | 220 M |
General and Administrative Expenses |
338 M | 353 M | 317 M | 363 M | 302 M | 273 M | 263 M | 243 M | 238 M | 244 M | 229 M | 235 M | 218 M | 191 M |
All numbers in USD currency
Quarterly Income Statement West Pharmaceutical Services
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
72.2 M | 72.2 M | 72.5 M | 72.3 M | 72.8 M | 73 M | 73.5 M | 73.5 M | 74.3 M | 74.3 M | 74.5 M | 74.1 M | 74.4 M | 74.4 M | 74.4 M | 74.2 M | 74.1 M | 74 M | 73.9 M | 74 M | 73.9 M | 73.8 M | 73.9 M | 74.1 M | 74 M | 73.7 M | 74.1 M | 74.1 M | 73.9 M | 73.6 M | 73.9 M | 73.9 M | 74.2 M | 73.9 M | 73.3 M | 73.1 M | 73.3 M | 73.3 M | 72.5 M | 72.3 M | 72.2 M | 72 M | 71.7 M | 71.3 M | 71 M | 70.8 M | 70.6 M | 70.2 M | 69.8 M | 69.5 M | 69 M | 68.6 M | 68.3 M | 34 M | 33.9 M | 33.7 M | 33.8 M | 33.6 M | 33.4 M |
Net Income |
140 M | 132 M | 89.8 M | - | 136 M | 111 M | 115 M | - | 161 M | 155 M | 140 M | - | 121 M | 188 M | 174 M | - | 176 M | 187 M | 151 M | 98.4 M | 82.3 M | 91.2 M | 74.3 M | 63.9 M | 56.3 M | 66.1 M | 55.4 M | - | 55.2 M | 56.1 M | 43.6 M | - | 51 M | 38.8 M | 60.9 M | - | 37.6 M | 44.7 M | 22.1 M | - | 1.5 M | 27.8 M | 32.9 M | - | 31 M | 37.6 M | 27.1 M | - | 26.8 M | 30.2 M | 31.7 M | - | 14.8 M | 15.6 M | 29.2 M | - | 16.9 M | 20.1 M | 19.6 M |
Revenue |
805 M | 766 M | 698 M | - | 747 M | 702 M | 695 M | - | 747 M | 754 M | 717 M | - | 687 M | 771 M | 720 M | - | 706 M | 724 M | 671 M | 580 M | 548 M | 527 M | 492 M | 471 M | 456 M | 470 M | 444 M | - | 432 M | 448 M | 416 M | - | 398 M | 398 M | 388 M | - | 377 M | 388 M | 362 M | - | 344 M | 360 M | 336 M | - | 356 M | 369 M | 347 M | - | 342 M | 344 M | 339 M | - | 304 M | 325 M | 316 M | - | 294 M | 308 M | 295 M |
Cost of Revenue |
510 M | 493 M | 466 M | - | 482 M | 472 M | 465 M | - | 459 M | 462 M | 445 M | - | 419 M | 450 M | 435 M | - | 418 M | 408 M | 399 M | - | 353 M | 332 M | 324 M | - | 308 M | 312 M | 297 M | - | 296 M | 305 M | 281 M | - | 273 M | 273 M | 254 M | - | 256 M | 255 M | 239 M | - | 236 M | 242 M | 226 M | - | 246 M | 247 M | 240 M | - | 236 M | 234 M | 228 M | - | 213 M | 226 M | 215 M | - | 212 M | 223 M | 207 M |
Gross Profit |
294 M | 274 M | 232 M | - | 265 M | 230 M | 230 M | - | 288 M | 291 M | 271 M | - | 268 M | 322 M | 285 M | - | 288 M | 315 M | 272 M | 211 M | 195 M | 195 M | 167 M | 153 M | 148 M | 158 M | 147 M | - | 136 M | 142 M | 134 M | - | 125 M | 125 M | 134 M | - | 121 M | 133 M | 123 M | - | 108 M | 118 M | 110 M | - | 110 M | 122 M | 106 M | - | 106 M | 111 M | 112 M | - | 90.4 M | 98.7 M | 101 M | - | 81.4 M | 84.6 M | 88 M |
Operating Income |
168 M | 154 M | 107 M | - | 161 M | 126 M | 123 M | - | 177 M | 182 M | 155 M | - | 186 M | 228 M | 190 M | - | 181 M | 211 M | 176 M | - | 99.2 M | 104 M | 88 M | - | 67.3 M | 80.5 M | 70.7 M | - | 60.8 M | 60.3 M | 53.4 M | - | 62.9 M | 42 M | 60.5 M | - | 51.3 M | 61.2 M | 30 M | - | -3.5 M | 39.1 M | 47.8 M | - | 44 M | 54.1 M | 39.3 M | - | 39.7 M | 42.5 M | 43.3 M | - | 26.3 M | 35.6 M | 41.7 M | - | 26.1 M | 27.8 M | 28.8 M |
Interest Expense |
-200 K | -200 K | -200 K | - | -700 K | - | 1.6 M | - | 2.9 M | 100 K | 2.2 M | - | 2.2 M | 1.8 M | 2.2 M | - | 1.8 M | 1.9 M | 1.9 M | - | 2.1 M | 2 M | 2 M | - | 2.1 M | 2 M | 2.3 M | - | 2 M | 2.2 M | 1.9 M | - | 1.4 M | 2.2 M | 2.1 M | - | 2.2 M | 2 M | 2.5 M | - | 3.7 M | 3.4 M | 4.1 M | - | 4.5 M | 4.2 M | 4 M | - | 4.4 M | 4.1 M | 4.6 M | - | 4.4 M | 4.6 M | 4.3 M | - | 4.5 M | 4.6 M | 4.7 M |
EBITDA |
211 M | 195 M | 147 M | - | 202 M | 165 M | 158 M | - | - | - | 186 M | - | 273 M | 228 M | 218 M | - | 266 M | 211 M | 204 M | - | 176 M | 154 M | 113 M | - | 142 M | 131 M | 95.6 M | - | 137 M | 111 M | 79.1 M | - | 133 M | 87.4 M | 83.1 M | - | 117 M | 105 M | 51.6 M | - | 60.1 M | 81.2 M | 68.8 M | - | 108 M | 96.7 M | 59.9 M | - | 99.6 M | 81.6 M | 62.7 M | - | 79.9 M | 70.8 M | 59.2 M | - | 80 M | 64.3 M | 47.1 M |
General and Administrative Expenses |
103 M | 95.9 M | 88 M | - | 83.5 M | 83 M | 86.7 M | - | 89 M | 88.4 M | 86 M | - | 66.3 M | 81.5 M | 83.4 M | - | 91.9 M | 92.7 M | 80.2 M | - | 76.2 M | 77.7 M | 71.8 M | - | 64.8 M | 70.3 M | 68.6 M | - | 64.9 M | 70 M | 68.3 M | - | 62.6 M | 61.3 M | 62.5 M | - | 58.3 M | 62.5 M | 58.1 M | - | 54.6 M | 60.8 M | 55.2 M | - | 56 M | 57.5 M | 56.4 M | - | 56.1 M | 59.7 M | 59.1 M | - | 53.7 M | 54.4 M | 51.3 M | - | 45.7 M | 46.4 M | 50.6 M |
All numbers in USD currency
Main types of financial statements West Pharmaceutical Services WSTFinancial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.
- Income Statement
Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability. - Balance Sheet
Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
Liabilities — debts and other external sources of financing.
Equity — owners' capital and retained earnings. - Cash Flow Statement
Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
- IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
- GAAP — Generally Accepted Accounting Principles used in the United States.
- RAS — Russian Accounting Standards, used domestically in Russia.
Financial reporting West Pharmaceutical Services plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.
In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.
Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.
Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.
Financial statements of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
BioLife Solutions
BLFS
|
$ 24.56 | 0.7 % | $ 1.13 B | ||
|
Baxter International
BAX
|
$ 19.52 | 1.93 % | $ 9.96 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 200.48 | -0.23 % | $ 57.7 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Ekso Bionics Holdings
EKSO
|
$ 4.68 | 0.21 % | $ 94.4 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Harvard Bioscience
HBIO
|
$ 0.71 | -4.45 % | $ 30.1 M | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
ICU Medical
ICUI
|
$ 148.28 | -0.1 % | $ 3.62 B | ||
|
iRhythm Technologies
IRTC
|
$ 170.21 | 0.82 % | $ 5.31 B | ||
|
Alcon
ALC
|
$ 79.15 | 0.43 % | $ 40.4 B | ||
|
AtriCure
ATRC
|
$ 41.07 | -3.09 % | $ 1.93 B | ||
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
electroCore
ECOR
|
$ 4.85 | 2.11 % | $ 26.7 K | ||
|
Repro Med Systems
KRMD
|
$ 5.8 | 0.35 % | $ 264 M | ||
|
AngioDynamics
ANGO
|
$ 13.42 | 2.13 % | $ 548 M | ||
|
The Cooper Companies
COO
|
$ 81.36 | -0.88 % | $ 16.2 B | ||
|
LeMaitre Vascular
LMAT
|
$ 83.04 | -1.14 % | $ 1.86 B | ||
|
Glaukos Corporation
GKOS
|
$ 111.73 | 2.6 % | $ 5.41 B | ||
|
Masimo Corporation
MASI
|
$ 137.35 | -0.72 % | $ 7.32 B | ||
|
Haemonetics Corporation
HAE
|
$ 80.24 | -3.89 % | $ 4.04 B | ||
|
InfuSystem Holdings
INFU
|
$ 9.22 | -0.27 % | $ 190 M | ||
|
Merit Medical Systems
MMSI
|
$ 86.49 | -0.24 % | $ 5.04 B | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Intuitive Surgical
ISRG
|
$ 559.7 | 3.2 % | $ 199 B | ||
|
OraSure Technologies
OSUR
|
$ 2.49 | - | $ 185 M | ||
|
Microbot Medical
MBOT
|
$ 2.23 | -7.65 % | $ 22.7 M | ||
|
Milestone Scientific
MLSS
|
$ 0.36 | -7.4 % | $ 28.7 M | ||
|
Nephros
NEPH
|
$ 4.98 | -0.8 % | $ 51.7 M | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
ResMed
RMD
|
$ 251.67 | -0.27 % | $ 36.8 B | ||
|
Envista Holdings Corporation
NVST
|
$ 22.07 | 0.46 % | $ 3.8 B | ||
|
Pro-Dex
PDEX
|
$ 44.0 | 1.43 % | $ 145 M | ||
|
STAAR Surgical Company
STAA
|
$ 23.49 | -2.65 % | $ 1.15 B | ||
|
STERIS plc
STE
|
$ 253.98 | 0.82 % | $ 25 B | ||
|
Stereotaxis
STXS
|
$ 2.35 | -1.05 % | $ 190 M | ||
|
Pulse Biosciences
PLSE
|
$ 14.04 | -1.4 % | $ 674 M | ||
|
Predictive Oncology
POAI
|
- | - | $ 32.4 M | ||
|
Repligen Corporation
RGEN
|
$ 160.09 | 1.72 % | $ 8.92 M | ||
|
Utah Medical Products
UTMD
|
$ 57.54 | -0.96 % | $ 209 M | ||
|
DENTSPLY SIRONA
XRAY
|
$ 11.43 | -1.21 % | $ 2.32 B | ||
|
Retractable Technologies
RVP
|
$ 0.84 | 1.99 % | $ 25.1 M | ||
|
Teleflex Incorporated
TFX
|
$ 126.88 | 0.17 % | $ 5.94 B |